Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non–small cell lung cancer
Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …
OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non …
F Wen, H Zheng, P Zhang, D Hutton, Q Li - BMJ open, 2018 - bmjopen.bmj.com
Objectives Erlotinib, the first generation of epidermoid growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI), has been recommended as an essential treatment in patients with non …
inhibitor (EGFR-TKI), has been recommended as an essential treatment in patients with non …
[HTML][HTML] Trial-based cost-utility analysis of icotinib versus gefitinib as second-line therapy for advanced non-small cell lung cancer in China
C Zhang, H Zhang, J Shi, D Wang, X Zhang, J Yang… - PloS one, 2016 - journals.plos.org
Background Our objective is to compare the cost-utility of icotinib and gefitinib for the second-
line treatment of advanced non-small cell lung cancer (NSCLC) from the perspective of the …
line treatment of advanced non-small cell lung cancer (NSCLC) from the perspective of the …
[HTML][HTML] Cost-effectiveness and value of information of erlotinib, afatinib, and cisplatin-pemetrexed for first-line treatment of advanced EGFR mutation-positive non …
J Ting, PDT Ho, P Xiang, A Sugay, M Abdel-Sattar… - Value in Health, 2015 - Elsevier
Objectives To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or
afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial …
afatinib, or chemotherapy cisplatin-pemetrexed, for first-line treatment of advanced epithelial …
[HTML][HTML] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
L Westerink, JLJ Nicolai, C Samuelsen… - The European Journal of …, 2020 - Springer
Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled …
Background There is a major unmet need for effective treatments in patients with squamous
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …
cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family …
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
J Aguilar-Serra, V Gimeno-Ballester… - Expert Review of …, 2022 - Taylor & Francis
Aim To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib,
afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC …
afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC …
[HTML][HTML] Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 …
Background LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib
and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma …
and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma …
Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis
PS Bajaj, DL Veenstra, HP Goertz… - Journal of medical …, 2014 - Taylor & Francis
Objectives: A recent phase III trial showed that patients with advanced non-small cell lung
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …
cancer (NSCLC) whose tumors harbor specific EGFR mutations significantly benefit from first …
A systematic review of pharmacoeconomic evaluations of erlotinib in the first-line treatment of advanced non-small cell lung cancer
CTT Nguyen, F Petrelli, S Scuri, BT Nguyen… - The European Journal of …, 2019 - Springer
Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …